Jordi Mons

List of Publications by Year in Descending Order

46 papers	1,895 citations	21 h-index	43 g-index
47 ext. papers	2,356 ext. citations	4.2 avg, IF	4.41 L-index

#	Paper	IF	Citations
46	A 10-point score classification for anti-VEGF response in exudative AMD. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2021**, 1	3.8	
45	Non-neovascular age-related macular degeneration with subretinal fluid. *British Journal of Ophthalmology*, **2021**, 105, 1415-1420	5.5	14
44	Reply. *Ophthalmology*, **2021**, 128, e26-e27	7.3	
43	Early Detection of Incipient Retinal Pigment Epithelium Atrophy Overlying Drusen with Fundus Autofluorescence . Spectral Domain Optical Coherence Tomography. *Journal of Ophthalmology*, **2020**, 2020, 9457457	2	1
42	Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy. *European Journal of Ophthalmology*, **2020**, 30, 1082-1090	1.9	2
41	Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration: Evidence from the EYE-RISK and European Eye Epidemiology Consortia. *Ophthalmology*, **2019**, 126, 393-406	7.3	49
40	Mediterranean Diet and Incidence of Advanced Age-Related Macular Degeneration: The EYE-RISK Consortium. *Ophthalmology*, **2019**, 126, 381-390	7.3	44
39	Performance characteristics of multicolor versus blue light and infrared imaging in the identification of reticular pseudodrusen. *International Ophthalmology*, **2018**, 38, 199-206	2.2	4
38	Reply. *Ophthalmology Retina*, **2018**, 2, e1-e2	3.8	
37	Geographic atrophy phenotype identification by cluster analysis. *British Journal of Ophthalmology*, **2018**, 102, 388-392	5.5	10
36	Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration: Results with Ranibizumab from the TREND Study. *Ophthalmology*, **2018**, 125, 57-65	7.3	145
35	Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study. *Ophthalmology Retina*, **2018**, 2, 134-142	3.8	16
34	Precision medicine for age-related macular degeneration: current developments and prospects. *Expert Review of Precision Medicine and Drug Development*, **2018**, 3, 249-263	1.6	2
33	The Rate of Progression of Geographic Atrophy Decreases With Increasing Baseline Lesion Size Even After the Square Root Transformation. *Translational Vision Science and Technology*, **2018**, 7, 40	3.3	12
32	Drusen Ooze: A Novel Hypothesis in Geographic Atrophy. *Ophthalmology Retina*, **2017**, 1, 461-473	3.8	9
31	Retinal Vein Occlusions. *Developments in Ophthalmology*, **2017**, 58, 139-167		23
30	Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. *Ophthalmology*, **2017**, 124, 1753-1763	7.3	220

29	Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial. *Ophthalmology*, **2017**, 124, 224-234	7.3	81
28	Correspondence. *Retina*, **2016**, 36, e20	3.6	2
27	Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study. *Ophthalmology*, **2016**, 123, 1101-11	7.3	70
26	A Swine Model of Selective Geographic Atrophy of Outer Retinal Layers Mimicking Atrophic AMD: A Phase I Escalating Dose of Subretinal Sodium Iodate **2016**, 57, 3974-83		42
25	FEEDER VESSEL LASER PHOTOCOAGULATION FOR IDIOPATHIC, SUBFOVEAL POLYPOIDAL CHOROIDAL VASCULOPATHY NOT RESPONDING TO EITHER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY OR PHOTODYNAMIC THERAPY. *Retinal Cases and Brief Reports*, **2016**, 10, 100-3	1.1	2
24	Individualized Stabilization Criteria-Driven Ranibizumab versus Laser in Branch Retinal Vein Occlusion: Six-Month Results of BRIGHTER. *Ophthalmology*, **2016**, 123, 1332-44	7.3	58
23	Increased Fundus Autofluorescence and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GAIN Study. *American Journal of Ophthalmology*, **2015**, 160, 345-353.e5	4.9	42
22	Scheduled versus Pro Re Nata Dosing in the VIEW Trials. *Ophthalmology*, **2015**, 122, 2497-503	7.3	28
21	TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. *Retina*, **2015**, 35, 1489-506	3.6	171
20	Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration. *Journal of Ophthalmology*, **2015**, 2015, 412903	2	10
19	Ranibizumab in retinal vein occlusion: treatment recommendations by an expert panel. *British Journal of Ophthalmology*, **2015**, 99, 297-304	5.5	29
18	Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). *British Journal of Ophthalmology*, **2014**, 98, 1144-67	5.5	308
17	A delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration. *Journal of Ophthalmology*, **2014**, 2014, 595132	2	7
16	Reappraisal of geographic atrophy patterns seen on fundus autofluorescence using a latent class analysis approach. *Investigative Ophthalmology and Visual Science*, **2014**, 55, 8302-8		6
15	Optical coherence tomography assessment of apparent foveal swelling in patients with foveal sparing secondary to geographic atrophy. *Ophthalmology*, **2013**, 120, 829-36	7.3	10
14	Intravitreal injections: a healthcare failure modes and effects analysis. *Ophthalmologica*, **2013**, 230, 151-64	3.7	3
13	Bimonthly half-dose ranibizumab in large pigment epithelial detachment and retinal angiomatous proliferation with high risk of retinal pigment epithelium tear: a case report. *Clinical Ophthalmology* , **2013**, 7, 1089-92	2.5	4
12	FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2012**, 250, 1737-44	3.8	16

11	Hyporeflective wedge-shaped band in geographic atrophy secondary to age-related macular degeneration: an underreported finding. *Ophthalmology*, **2012**, 119, 1412-9	7.3	35
10	Intra and interobserver agreement in the classification of fundus autofluorescence patterns in geographic atrophy secondary to age-related macular degeneration. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2012**, 250, 485-90	3.8	11
9	Management of retinal vein occlusion--consensus document. *Ophthalmologica*, **2011**, 226, 4-28	3.7	88
8	Postsurgical cystoid macular edema. *European Journal of Ophthalmology*, **2011**, 21 Suppl 6, S62-8	1.9	23
7	As-needed treatment with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration. *European Journal of Ophthalmology*, **2011**, 21, 282-9	1.9	14
6	Update on geographic atrophy in age-related macular degeneration. *Optometry and Vision Science*, **2011**, 88, 881-9	2.1	23
5	A review of ranibizumab clinical trial data in exudative age-related macular degeneration and how to translate it into daily practice. *Ophthalmologica*, **2011**, 225, 112-9	3.7	12
4	Retinal vein occlusions. *Developments in Ophthalmology*, **2010**, 47, 111-135		65
3	Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study. *Pharmacoeconomics*, **2008**, 26, 57-73	4.4	75
2	Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study. *JAMA Ophthalmology*, **2007**, 125, 1249-54		108
1	New perspectives on the treatment of age-related macular degeneration. *Drugs of Today*, **2005**, 41, 701	2.5	